Cellectis (NASDAQ:CLLS) PT Lowered to $6.00

Cellectis (NASDAQ:CLLSGet Rating) had its price target decreased by stock analysts at JMP Securities from $11.00 to $6.00 in a research report issued to clients and investors on Thursday, The Fly reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price objective indicates a potential upside of 96.08% from the stock’s previous close.

Several other equities research analysts have also recently commented on the company. Citigroup dropped their price objective on Cellectis from $36.00 to $24.00 in a research report on Wednesday, December 14th. StockNews.com raised Cellectis from a “sell” rating to a “hold” rating in a research report on Saturday, December 3rd.

Cellectis Price Performance

Shares of NASDAQ:CLLS opened at $3.06 on Thursday. Cellectis has a 1-year low of $1.83 and a 1-year high of $7.03. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.65 and a quick ratio of 2.65. The business has a fifty day moving average price of $2.45 and a 200-day moving average price of $2.70. The company has a market capitalization of $139.47 million, a PE ratio of -1.33 and a beta of 1.95.

Cellectis (NASDAQ:CLLSGet Rating) last released its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.05). Cellectis had a negative net margin of 470.32% and a negative return on equity of 54.50%. The business had revenue of $1.92 million for the quarter, compared to analysts’ expectations of $22.45 million. As a group, equities analysts expect that Cellectis will post -2.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Capital Wealth Alliance LLC purchased a new position in Cellectis in the second quarter worth about $680,000. Principal Financial Group Inc. boosted its position in Cellectis by 11.0% in the second quarter. Principal Financial Group Inc. now owns 1,348,312 shares of the biotechnology company’s stock worth $3,816,000 after purchasing an additional 133,587 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Cellectis by 30.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 186,018 shares of the biotechnology company’s stock worth $526,000 after purchasing an additional 43,677 shares during the last quarter. State Street Corp boosted its position in Cellectis by 3.7% in the first quarter. State Street Corp now owns 119,561 shares of the biotechnology company’s stock worth $543,000 after purchasing an additional 4,297 shares during the last quarter. Finally, Vanguard Group Inc. purchased a new position in shares of Cellectis during the 3rd quarter valued at about $197,000. 22.61% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

(Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Read More

The Fly logo

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.